Key clinical point: An agent against a common oral bacteria was seen reducing some markers of Alzheimer’s disease (AD).
Major finding: CSF levels of an AD-associated apolipoprotein E (ApoE) fragment and serum levels of RANTES, a chemokine associated with chronic inflammation, were reduced from baseline by about one-third in treated subjects, compared with placebo subjects (P less than .05).
Study details: A small, placebo-controlled trial enrolling nine subjects with mild to moderate AD.
Disclosures: Cortexyme, the maker of the experimental antimicrobial drug, sponsored the study, and 9 of the study’s 11 authors were employees.
FROM AAIC 2019